Clinical parameters | Before PSM | After PSM | ||||
---|---|---|---|---|---|---|
Non-PORT (N = 2535) | PORT (N = 1446) | P-value | Non-PORT (N = 1380) | PORT (N = 1380) | P-value | |
Age, years (range) | 67 (22–90) | 64 (19–88) | < 0.001* | 65 (22–89) | 65 (28–88) | 0.674 |
Sex | 0.942 | 0.469 | ||||
Male | 1253 (49.43%) | 713 (49.31%) | 669 (48.48%) | 688 (49.86%) | ||
Female | 1282 (50.57%) | 733 (50.69%) | 711 (51.52%) | 692 (50.14%) | ||
Race | 0.585 | 0.591 | ||||
Black | 256 (10.10%) | 141 (9.75%) | 152 (11.01%) | 136 (9.86%) | ||
White | 2051 (80.91%) | 1161 (80.29%) | 1091 (79.06%) | 1109 (80.36%) | ||
Others or unknown | 228 (8.99%) | 144 (9.96%) | 137 (9.93%) | 135 (9.78%) | ||
Year of diagnosis | < 0.001* | 0.360 | ||||
2004–2009 | 1370 (54.04%) | 645 (44.61%) | 653 (47.32%) | 629 (45.58%) | ||
2010–2015 | 1165 (45.96%) | 801 (55.39%) | 727 (52.68%) | 751 (54.42%) | ||
Laterality | 0.154 | 0.378 | ||||
Right | 1373 (54.16%) | 817 (56.50%) | 760 (55.07%) | 783 (56.74%) | ||
Left | 1162 (45.84%) | 629 (43.50%) | 620 (44.93%) | 597 (43.26%) | ||
Primary site | 0.021* | 0.766 | ||||
Main bronchus | 30 (1.18%) | 16 (1.11%) | 18 (1.30%) | 15 (1.09%) | ||
Upper lobe | 1415 (55.82%) | 869 (60.10%) | 793 (57.46%) | 822 (59.57%) | ||
Middle lobe | 113 (4.46%) | 74 (5.12%) | 67 (4.86%) | 71 (5.14%) | ||
Lower lobe, | 911 (35.94%) | 463 (32.02%) | 476 (34.49%) | 448 (32.46%) | ||
Overlapping lesion of lung | 66 (2.60%) | 24 (1.66%) | 26 (1.88%) | 24 (1.74%) | ||
Tumor size, mm (range) | 35 (1–195) | 35 (5–180) | 0.325 | 35 (1–190) | 34 (5–180) | 0.584 |
Histologic type | 0.136 | 0.876 | ||||
Adenocarcinoma | 1622 (63.98%) | 970 (67.08%) | 920 (66.67%) | 912 (66.09%) | ||
Squamous cell carcinoma | 597 (23.55%) | 307 (21.23%) | 292 (21.16%) | 303 (21.96%) | ||
Others | 316 (12.47%) | 169 (11.69%) | 168 (12.17%) | 165 (11.96%) | ||
Grade | 0.604 | 0.855 | ||||
Well differentiated | 126 (4.97%) | 58 (4.01%) | 64 (4.64%) | 55 (3.99%) | ||
Moderately differentiated | 1062 (41.89%) | 603 (41.70%) | 586 (42.46%) | 574 (41.59%) | ||
Poorly differentiated | 1132 (44.65%) | 655 (45.30%) | 611 (44.28%) | 625 (45.29%) | ||
Undifferentiated; anaplastic | 64 (2.52%) | 34 (2.35%) | 34 (2.46%) | 33 (2.39%) | ||
Unknown | 151 (5.96%) | 96 (6.64%) | 85 (6.16%) | 93 (6.74%) | ||
Surgical procedure | < 0.001* | 0.239 | ||||
Lobectomy | 2229 (87.93%) | 1324 (91.56%) | 1242 (90.00%) | 1260 (91.30%) | ||
Pneumonectomy | 306 (12.07%) | 122 (8.44%) | 138 (10.00%) | 120 (8.70%) | ||
T stage (sixth edition) | 0.075 | 0.122 | ||||
T1 | 697 (27.50%) | 411 (28.42%) | 391 (28.33%) | 391 (28.33%) | ||
T2 | 1667 (65.76%) | 912 (63.07%) | 899 (65.14%) | 871 (63.12%) | ||
T3 | 171 (6.75%) | 123 (8.51%) | 90 (6.52%) | 118 (8.55%) | ||
LN examined (range) | 11 (1–90) | 11 (1–79) | 0.812 | 11 (1–90) | 11 (1–79) | 0.595 |
Metastatic LN | < 0.001* | 0.644 | ||||
> 4 | 630 (24.85%) | 450 (31.12%) | 392 (28.41%) | 403 (29.20%) | ||
<=4 | 1905 (75.15%) | 996 (68.88%) | 988 (71.59%) | 977 (70.80%) | ||
Positive LN ratio (%) | < 0.001* | 0.386 | ||||
> 50 | 488 (19.25%) | 376 (26.00%) | 301 (21.81%) | 320 (23.19%) | ||
<=50 | 2047 (80.75%) | 1070 (74.00%) | 1079 (78.19%) | 1060 (76.81%) | ||
Chemotherapy | < 0.001* | 0.673 | ||||
No | 1028 (40.55%) | 151 (10.44%) | 158 (11.45%) | 151 (10.94%) | ||
Yes | 1507 (59.45%) | 1295 (89.56%) | 1222 (88.55%) | 1229 (89.06%) | ||
Median FU, months (range) | 27 (1–154) | 28 (1–154) | 0.010* | 29 (1–154) | 28.5 (1–154) | 0.852 |